Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
ranibizumab (lucentis) (1 trial)
urea (1 trial)
verteporfin (visudyne) (1 trial)
Choroidal Neovascularization (Phase 2)
Macular Degeneration (Phase 2)
Neovascularization, Pathologic (Phase 2)
Trials (1 total)
Trial APIs (3 total)